Geron Corp (GERN)
3.81
-0.09
(-2.31%)
USD |
NASDAQ |
May 17, 16:00
3.82
+0.01
(+0.26%)
After-Hours: 20:00
Geron Research and Development Expense (TTM): 127.20M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 127.20M |
| December 31, 2023 | 125.05M |
| September 30, 2023 | 120.34M |
| June 30, 2023 | 115.52M |
| March 31, 2023 | 100.64M |
| December 31, 2022 | 95.52M |
| September 30, 2022 | 91.46M |
| June 30, 2022 | 85.38M |
| March 31, 2022 | 86.71M |
| December 31, 2021 | 85.73M |
| September 30, 2021 | 77.80M |
| June 30, 2021 | 72.89M |
| March 31, 2021 | 61.80M |
| December 31, 2020 | 51.49M |
| September 30, 2020 | 60.18M |
| June 30, 2020 | 57.68M |
| March 31, 2020 | 56.97M |
| December 31, 2019 | 52.07M |
| September 30, 2019 | 32.23M |
| June 30, 2019 | 23.83M |
| March 31, 2019 | 16.90M |
| December 31, 2018 | 13.43M |
| September 30, 2018 | 10.87M |
| June 30, 2018 | 10.80M |
| March 31, 2018 | 10.10M |
| Date | Value |
|---|---|
| December 31, 2017 | 11.03M |
| September 30, 2017 | 12.63M |
| June 30, 2017 | 14.31M |
| March 31, 2017 | 16.39M |
| December 31, 2016 | 18.05M |
| September 30, 2016 | 17.91M |
| June 30, 2016 | 17.64M |
| March 31, 2016 | 17.88M |
| December 31, 2015 | 17.83M |
| September 30, 2015 | 18.20M |
| June 30, 2015 | 20.14M |
| March 31, 2015 | 20.48M |
| December 31, 2014 | 20.71M |
| September 30, 2014 | 21.44M |
| June 30, 2014 | 20.79M |
| March 31, 2014 | 20.44M |
| December 31, 2013 | 23.23M |
| September 30, 2013 | 29.94M |
| June 30, 2013 | 36.29M |
| March 31, 2013 | 44.26M |
| December 31, 2012 | 51.37M |
| September 30, 2012 | 59.24M |
| June 30, 2012 | 63.90M |
| March 31, 2012 | 67.67M |
| December 31, 2011 | 69.32M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
23.83M
Minimum
Jun 2019
127.20M
Maximum
Mar 2024
79.02M
Average
81.59M
Median
Research and Development Expense (TTM) Benchmarks
| Madrigal Pharmaceuticals Inc | 281.43M |
| SELLAS Life Sciences Group Inc | 21.94M |
| Johnson & Johnson | 15.30B |
| Pfizer Inc | 10.67B |
| Immuneering Corp | 42.62M |